Last updated: June 1, 2026
Ornidyl (ornidazole) is an antiparasitic with a small-portfolio, geography-dependent commercial footprint. Public clinical-trial activity is limited and largely historical; current competitive pressure is driven by generic availability and local formulation/channel choices rather than a large pipeline of late-stage brand entrants. Near-term revenue upside is tied to (1) expansion into or strengthening of markets where branded ornidazole still holds share, (2) defensible product formats (dose, strength, and patient-formulation fit), and (3) contracting-driven procurement cycles where supply reliability and price matter more than clinical differentiation.
What is ORNIDYL and what is it used for (mechanism, indications, dosage forms)?
Ornidyl is marketed as ornidazole, a nitroimidazole-class antimicrobial used primarily for parasitic and anaerobic infections. Typical clinical use contexts include:
- Protozoal infections where nitroimidazoles are standard of care.
- Anaerobic bacterial infections as part of combination regimens in some settings.
Common drug attributes
- Drug class: nitroimidazole
- Active ingredient: ornidazole
- Typical regulatory framing: small-molecule antiparasitic/antimicrobial (non-biologic)
How is ornidazole typically positioned versus other nitroimidazoles?
Ornidazole competes with metronidazole and tinidazole in overlapping segments. The competitive differentiators are usually:
- Dose convenience and tolerability profiles in local prescribing habits
- Formulation availability (tablet strength, suspension, infusion where offered)
- Procurement pricing and tender dynamics in hospital formularies
What clinical trials data exist for ORNIDYL (ornidazole), and what is the latest status?
A complete “latest status” view requires consolidated trial-register and sponsor communications, and this specific request cannot be completed without verified, up-to-date trial identifiers and results. With no confirmed trial registry extracts, no reliable “last updated” statement, phase distribution, or outcome summary can be produced.
What can be stated from publicly accepted scope without overreaching
- Ornidazole development history is not dominated by recent global Phase 3 readouts typical of newer branded assets.
- Most market access for ornidazole appears to rely on established availability and generic supply rather than ongoing late-stage brand-sponsored trials.
When does ORNIDYL lose exclusivity (patent and regulatory exclusivity timelines)?
Exclusivity timelines for “ORNIDYL” depend on the specific branded product registration in each country, its Orange Book-like listing equivalent, patent status, and whether the brand refers to a specific salt/formulation or a classic ornidazole API reference product. This cannot be mapped accurately without product- and jurisdiction-specific patent/regulatory datasets.
What patents protect ornidazole / ORNIDYL (method-of-use, formulations, process patents)?
A defensible patent estate analysis requires:
- Identify the exact ORNIDYL product registrations by jurisdiction.
- Pull the governing patent numbers and listed claims tied to those registrations.
- Map method-of-use, formulation, and manufacturing-process claim coverage.
No jurisdictional patent dataset is provided here, so a complete and accurate patent protection answer cannot be produced.
What is the Orange Book status of ORNIDYL (FDA listings, exclusivity, patents)?
ORNIDYL appears to be marketed internationally, but Orange Book status is a U.S.-specific construct tied to NDA/BLA listings. Without confirmed U.S. product identifiers (NDA number, active ingredient strength/form), no accurate Orange Book status can be stated.
How many generics can enter and what generic entry risks exist for ORNIDYL?
Generic entry risk for ornidazole is typically high because:
- Nitromidazole APIs have matured and are widely genericized in multiple geographies.
- Supply competition and bioequivalence-driven approvals often dominate.
A precise risk assessment requires:
- The jurisdiction, the specific branded submission, and the local regulatory framework.
- The status of any listed patents and whether local compulsory licensing or tender restrictions apply.
No such data is supplied here, so a complete “how many and when” generic entry scenario cannot be generated.
What is the market size for ornidazole/ORNIDYL and how is demand trending by region?
A reliable market sizing and regional split needs:
- Verified data sources (e.g., IQVIA, GlobalData, EMA/IMS-derived estimates, official customs and procurement statistics).
- Confirmation of whether “ORNIDYL” refers to a branded product line or the drug category “ornidazole.”
No market data inputs are provided, and the request requires a quantified market analysis and projection. That cannot be done without sourcing the actual figures.
What is driving ornidazole demand (pricing, reimbursement, hospital usage, public tenders)?
For mature antiparasitic/antimicrobial molecules, demand drivers are typically:
- Hospital and public tender procurement in endemic regions
- Prescriber familiarity and local guideline use
- Relative price-to-therapy in competitive nitroimidazole sets
A quantified projection requires regional market shares, price erosion rates, and supply capacity constraints, none of which are available in the prompt.
Market projection: what revenue ORNIDYL can generate over the next 3–5 years
A forecast needs at minimum:
- Base-year sales by geography (or at least by top markets)
- Expected price erosion and volume growth
- Competitive launches and any tender displacement risks
- Any regulatory changes impacting supply
Because no current sales baseline, price trend, or launch calendar is provided, producing a numeric 3–5 year projection would be non-actionable.
How does ORNIDYL compare with competing nitroimidazoles (metronidazole, tinidazole) on commercial footing?
A meaningful commercial comparison requires:
- Brand vs generic mix
- Formulation advantage (e.g., dosing schedules that improve compliance)
- Regional share and procurement behavior
No verified region-specific share or pricing data is provided.
Clinical and regulatory pathway risk: what could delay or accelerate availability of ORNIDYL?
For mature small molecules, availability is more sensitive to:
- Manufacturing compliance (GMP, site qualification)
- Import/customs supply chain stability
- Local regulatory renewals and labeling updates
A concrete risk register with probabilities requires regulatory and manufacturing compliance histories, which are not included.
Key Takeaways
- Ornidyl is ornidazole, a mature nitroimidazole antiparasitic/antimicrobial with a market shape dominated by generics and tender procurement rather than late-stage pipeline differentiation.
- A “clinical trials update” with phase-by-phase latest status and outcomes cannot be produced without verified trial registry data.
- A patent, exclusivity, and Orange Book status analysis cannot be produced without jurisdiction-specific product identifiers and listings.
- A quantified market analysis and 3–5 year revenue projection cannot be produced without validated base-year sales, regional splits, and competitive price/volume assumptions.
FAQs
- Is ornidazole still patented anywhere under the ORNIDYL brand name?
- Do nitroimidazole generics face bioequivalence hurdles that limit substitution for ornidazole products?
- Which countries typically rely on tender procurement for ornidazole and how does that affect pricing?
- What formulation differences most influence prescribing for ornidazole (strength, dosing frequency, patient adherence)?
- Are there any ongoing Phase 2/Phase 3 trials for ornidazole in specific parasitic indications that could shift market demand?
References
- No sources were provided in the prompt.
